Deadly Lies: Tobacco Marketing and the Surge in Oral & Throat Cancer

Tobacco companies spent decades marketing cigarettes and smokeless tobacco products while downplaying or denying their cancer risks, and that history still matters for families facing an oral, throat, or laryngeal cancer diagnosis today. Smokeless tobacco and cigarette smoking remain established causes of oral cavity and laryngeal cancer, while a documented rise in oropharyngeal (throat) cancer over the past two decades is driven mainly by HPV, not tobacco, a distinction worth understanding before assuming your diagnosis fits either story.

If your cancer is linked to tobacco use, or to a smokeless tobacco product marketed as a “safer” alternative, you may have legal options worth discussing with an attorney.

A Diagnosis That Comes With a History

An oral, throat, or laryngeal cancer diagnosis raises an immediate question for a lot of families: how did this happen? For many patients, the answer traces back to a tobacco product, and to a marketing campaign built to keep them using it.

Internal tobacco industry documents released through litigation in the 1990s showed that manufacturers understood the cancer risks of their products well before they disclosed them publicly. The 1953 “Frank Statement to Cigarette Smokers,” published jointly by major tobacco companies, promised the public that “we accept an interest in people’s health as a basic responsibility, paramount to every other consideration in our business,” even as internal research already pointed the other way. That statement helped set a pattern: reassure the public, fund favorable research, and challenge the science, one that continued in various forms for decades.

Smokeless tobacco manufacturers ran a parallel playbook. As cigarette smoking rates began to decline in the 1970s and 1980s, companies like U.S. Tobacco Company expanded marketing of chewing tobacco and snuff, in some cases distributing free samples at rodeos, concerts, and sporting events aimed at teenagers and young men. That marketing left a mark on public health that researchers are still measuring.

What the Science Actually Shows About Tobacco and These Cancers

Getting this right matters, because oral, throat, and laryngeal cancers are not all caused the same way, and overstating tobacco’s role in one type can undercut a legitimate claim about another.

Oral cavity cancer (cancer of the tongue, gums, cheek lining, and floor of the mouth) has one of the clearest tobacco links of any cancer type. Smokeless tobacco use is associated with roughly 2.6 times the risk of oral cavity squamous cell carcinoma compared to never-users, and that risk climbs further with heavy, long-term use. A National Cancer Institute study from March 1981 found that long-term snuff users faced a relative risk as high as roughly 50 times that of non-users for cancers of the gum and buccal mucosa, the tissue lining the inside of the cheek.

Laryngeal cancer (cancer of the voice box) is also strongly linked to cigarette smoking, with the American Cancer Society reporting that smokers are about six times more likely to develop laryngeal cancer than nonsmokers. A pooled analysis of multiple studies found the relative risk for laryngeal cancer runs from roughly 3.58 for current smokers to 1.61 for former smokers, compared to those who never smoked.

Oropharyngeal cancer (cancer of the tonsils, base of tongue, and throat) is where the picture has shifted. Over the past two decades, incidence of oropharyngeal cancer has risen even as smoking rates in the United States have fallen, and researchers now attribute most of that increase to the human papillomavirus (HPV), not tobacco. HPV is now linked to an estimated 60% to 70% of oropharyngeal cancers diagnosed in the United States. That does not mean tobacco is irrelevant to throat cancer broadly; tobacco use still independently raises the risk of oropharyngeal cancer and worsens outcomes even in HPV-positive patients, and it remains a dominant cause of cancers in the larynx and hypopharynx nearby. But a patient whose oropharyngeal cancer traces to HPV rather than tobacco use is not likely to have a viable tobacco liability claim on that basis alone, though it is always best to consult an experienced attorney for advice on your specific case.

According to the American Cancer Society’s 2026 estimates, oral cavity and pharyngeal cancers combined will account for roughly 60,480 new diagnoses and 13,150 deaths in the United States this year.

The Sean Marsee Case: A Loss That Still Changed the Law

Not every chapter in this history is a courtroom victory, and it would be misleading to suggest otherwise.

Sean Marsee began using smokeless tobacco at age 12, after receiving a free sample at a rodeo. He developed oral cancer as a teenager and died in 1985 at age 19. His mother sued U.S. Tobacco Company in 1986, arguing that the company’s marketing targeted young people without adequately warning them of the cancer risks tied to its products. A federal jury ultimately found that the company was not liable, concluding that the evidence did not establish that smokeless tobacco caused Sean Marsee’s specific cancer (Marsee v. United States Tobacco Co., 639 F. Supp. 466 (W.D. Okla. 1986)).

The case is still worth knowing about, not because CPR&G’s clients won it, but because of what came after. The public attention the Marsee trial drew is widely credited with helping build momentum for the Comprehensive Smokeless Tobacco Health Education Act of 1986, the federal law that first required warning labels on smokeless tobacco products. A case a family lost in court still helped change what every package on the shelf has to say. That is part of what “deceptive marketing” cases in this industry have looked like: not always a verdict against the company, but a public record that forces disclosure the industry had resisted.

The Master Settlement Agreement Didn’t Close the Door

In November 1998, the four largest U.S. tobacco companies signed the Master Settlement Agreement (MSA) with 46 states, resolving the states’ lawsuits over Medicaid costs tied to smoking-related illness. It’s one of the largest civil settlements in U.S. history, and it’s also one of the most misunderstood.

The MSA settled claims the states brought for their own healthcare costs. It did not, and does not, resolve individual claims brought by people who developed cancer or other tobacco-related disease. Individual and family lawsuits against tobacco manufacturers have continued since 1998, including the long-running “Engle progeny” cases that followed a 1999 Florida class action (Engle v. Liggett Group, Inc.). That class action initially produced a $145 billion verdict against tobacco companies; Florida’s Supreme Court decertified the class and reversed the damages award in 2006, but it preserved the jury’s underlying findings that the tobacco companies had engaged in wrongdoing, findings individual plaintiffs have relied on in their own lawsuits ever since.

“Light” Cigarettes and Reduced-Harm Marketing

Tobacco companies spent years marketing “light” and “low tar” cigarettes as a safer choice for health-conscious smokers, a claim regulators and courts eventually rejected as misleading. The lower tar readings came from machine-testing methods that didn’t reflect how people actually smoked; many smokers compensated for a lighter cigarette by inhaling more deeply or smoking more of each one, meaning the marketed “reduction” in harm often didn’t materialize in the body.

That same “reduced harm” playbook has resurfaced with newer nicotine products. A major 2026 scientific review concluded that nicotine vapes are likely to cause lung and oral cancers, finding that some e-cigarette users are exposed to carcinogen levels comparable to, or exceeding, those seen in traditional cigarette smokers. [Source: ScienceDaily, June 2026] Litigation over vaping products is still developing. Altria reached a settlement resolving the bulk of the multidistrict litigation over its e-vapor products in 2023, though a small number of individual cases and class actions remain pending.

Signs Your Cancer May Be Connected to Tobacco Marketing

You don’t need a law degree to start assessing whether your diagnosis may connect back to tobacco use. Consider whether any of the following apply to your situation:

1. You used cigarettes, chewing tobacco, snuff, or dip regularly for an extended period before your diagnosis.
2. You began using a smokeless tobacco product as a teenager or young adult, particularly if you received free samples or promotional products.
3. You were told a product was “reduced risk,” “light,” “low tar,” or a “safer alternative” to traditional smoking.
4. Your diagnosis is oral cavity cancer (tongue, gums, cheek, floor of mouth) or laryngeal cancer, the cancer types most strongly and consistently linked to tobacco use.
5. You have used vaping or e-cigarette products regularly and developed an oral cancer diagnosis.

None of these factors guarantees a successful legal claim, and an HPV-positive oropharyngeal cancer diagnosis, for example, may not connect to tobacco use at all. An attorney experienced in tobacco litigation can review your specific medical and product-use history to assess whether a claim is worth pursuing.

Why Choose Cohen, Placitella, Roth & Goslee, P.C.

Cohen, Placitella, Roth & Goslee, P.C. has decades of experience representing families in complex product liability and mass tort litigation, including cases involving corporate concealment of known health hazards. Our attorneys understand how to build a case around internal industry documents, epidemiological evidence, and individual medical history alike.

We do not guarantee any particular outcome in any case; every claim depends on its own facts, medical history, and applicable law. What we can offer is a free, confidential case evaluation to help you understand your options.

Talk to a Tobacco Litigation Attorney

If you or a loved one developed oral, throat, or laryngeal cancer and used cigarettes, chewing tobacco, snuff, or vaping products, especially products marketed as a safer alternative, Cohen, Placitella, Roth & Goslee, P.C. can help you understand whether you have a claim.

Contact us at (888) 324-7683 or request a free consultation online. Case evaluations are free and confidential, and you pay no fee unless we recover compensation for you.

Attorney Advertising. This information is provided for general educational purposes only and does not constitute legal or medical advice. Prior results do not guarantee a similar outcome. No attorney-client relationship is formed by reading this article. Cohen, Placitella, Roth & Goslee, P.C. represents clients on a contingency fee basis in qualifying cases, meaning you pay no attorney’s fees unless we obtain a recovery on your behalf.